DDInter1352 DDInter1016
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Osimertinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Osimertinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Osimertinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Osimertinib {u} may lead to a major life threatening interaction when taken with {v} Tetrabenazine
Osimertinib {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Osimertinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Osimertinib may lead to a major life threatening interaction when taken with Tetrabenazine
Osimertinib may lead to a major life threatening interaction when taken with Entrectinib